Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Gemcitabine in HER2+ MIBC
NCT05723991Phase 4Unknown
- Start
- Sep 2022
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 4 trial of disitamab vedotin in Muscle Invasive Bladder Cancer (MIBC). Status: unknown.
02
Drugs
disitamab vedotin
03
Conditions
Muscle Invasive Bladder Cancer (MIBC)
Beyond the preview
Go deeper on NCT05723991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05723991.